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The bronchospasmolytic and secretolytic effects of ivy leaves dry extracts can be explained by an
increased b2-adrenergic responsiveness of the bronchi. Recently, it was shown that a-hederin inhibits the
internalization of b2-adrenergic receptors (ß2AR) under stimulating conditions. a-Hederin pretreated
alveolar type II cells and human airway smooth muscle cells revealed an increased ß2AR binding and an
elevated intracellular cAMP level, respectively. In order to identify whether additional compounds also
mediate an increased b2-adrenergic responsiveness, we examined the ingredients of an ivy leaves dry
extract (EA 575) protocatechuic acid, neochlorogenic acid, chlorogenic acid, cryptochlorogenic acid, rutin,
kaempferol-3-O-rutinoside, 3,4-, 3,5- and 4,5-dicaffeoylquinic acid, hederacoside B, and b-hederin.
Within all the tested substances, only b-hederin inhibited the internalization of GFP-tagged ß2AR in
stably transfected HEK293 cells. Using ﬂuorescence correlation spectroscopy b-hederin (1 mM, 24 h)
pretreated HASM cells showed a statistically signiﬁcant increase in the ß2AR binding from 33.0 ± 8.9% to
44.1 ± 11.5% which was distributed with 36.0 ± 9.5% for tbound1 and 8.1 ± 2.6% for tbound2, respectively
(n ¼ 8, p < 0.05). The increased binding was selectively found for the receptoreligand complex with
unrestricted lateral mobility (tbound1 of 0.9 ± 0.1 ms, D1 ¼ 9.1 ± 0.2 mm2/s, n ¼ 8), whereas the binding of
ß2AR with hindered lateral mobility (tbound2 of 64.2 ± 47.6 ms, D2 ¼ 0.15 ± 0.02 mm2/s, n ¼ 8) was not
affected. Compared to control cells, a statistically signiﬁcant increase of 17.5 ± 6.4% (n ¼ 4, p < 0.05) and
24.2 ± 5.8% (n ¼ 4, p < 0.001) in the cAMP formation was found for b-hederin pretreated HASM cells after
stimulation with 10 mM of terbutaline and simultaneous stimulation with 10 mM terbutaline and 10 mM
forskolin, respectively. Within this systematic study focusing on the inﬂuence of the ingredients of an ivy
leaves dry extract on HASM cells it was possible to identify b-hederin as further component presumably
responsible for the b2-mimetic effects.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Preparations of ivy leaves dry extract are used in the treatment
of upper respiratory tract conditions characterized by hypersecre-
tion of a viscous mucus and coughing. The extracts are well toler-
ated by children and adults suffering from acute or chronic
obstructive bronchitis and the efﬁcacy of a special extract (EA 575,
DER 5-7.5:1, 30% m/m EtOH) has been conﬁrmed by placebo
controlled clinical trials and post-marketing surveillance studies
[1e5]. Clinical improvements in lung function have been observed,: þ49 228 732416.
rlein).
Ltd. This is an open access article ubased on spirometric and plethysmographic measurements [1e4].
Ivy extracts show secretolytic and bronchospasmolytic effects,
which reduce the airway resistance and clear the respiratory
system.
Preclinical studies indicated a-hederin to be the main pharma-
cologic active compound of ivy leaves dry extracts by increasing the
b2-adrenergic responsiveness in alveolar type II (A549) cells and
human airway smooth muscle (HASM) cells [6]. a-Hederin inhibits
the internalization of b2-adrenergic receptors (ß2AR) even under
stimulating conditions. In fact, a-hederin pretreated A549 cells
showed an increased ß2AR binding [6]. This results in an increased
intracellular cAMP level, which subsequently elevates the surfac-
tant production and secretion in alveolar type II cells. Thus, the
secretolytic and bronchospasmolytic effect can be explained by annder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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of ivy leaves dry extracts was also demonstrated by an improved
isoprenaline mediated relaxation behavior of a-hederin pretreated
and methacholine precontracted airway smooth muscles [7].
Mainly, the ingredients of ivy leaves described in literature
belong to the natural product classes of saponins, ﬂavonoids and
phenolic acids. So far, saponins are considered as the pharmaco-
logical relevant compounds inﬂuencing the b2-adrenergic receptor
regulation. Besides a-hederin, the saponin hederacoside C is also
important. Hederacoside C can be considered as a prodrug due to its
conversion to a-hederin, following its resorption into the blood [8].
Whether other ingredients contribute to the indirect b2-mimetic
effect still remains unclear.
In this paper, we investigated the inﬂuence of the main sapo-
nins, ﬂavonoids and phenolic acids, identiﬁed from a therapeuti-
cally used ivy leaves dry extract (EA 575, DER 5-7.5:1, 30% m/m
EtOH), on b2-adrenergic receptor-GFP fusion proteins in stably
transfected HEK293 cells.
2. Materials and methods
2.1. Chemicals
Ivy leaves dry extract EA 575 was provided by Engelhard Arz-
neimittel GmbH Co.KG (Niederdorfelden, Germany).
3,4-, 3,5- and 4,5-dicaffeoylquinic acid, protocatechuic acid,
chlorogenic acid, neochlorogenic acid and cryptochlorogenic acid
were provided from Phytolab (Vestenbergsgreuth, Germany).
Rutin, kaempferol-3-O-rutinoside, and a-hederin were obtained
from HWI (Rülzheim, Germany). Hederacoside B was delivered by
ChromaDex (Irvine, CA, USA). b-Hederin was obtained by alkaline
hydrolysis of hederacoside B and subsequent isolation from the
reaction mixture by HPLC. Terbutaline hemisulfate was purchased
from Sigma (Taufkirchen, Germany). Synthesis, identity, and bind-
ing behavior of Alexa532-NA at b2-adrenergic receptors were re-
ported by our group [9].
2.2. Cell culture
Human airway smooth muscle (HASM) cells obtained from I.
Hall (Institute of Pharmaceutical Science and Experimental Thera-
peutics, University of Nottingham, Nottingham, UK) were culti-
vated in DMEM-F12 medium supplemented with 2 mM L-
glutamine, 100 units/mL penicillin, 100 mg/mL streptomycin, and
10% fetal calf serum. For ﬂuorescence correlation spectroscopy ex-
periments, cells were seeded at a density of 1.7e3.4  104 cells/cm2
on heat-sterilized glass coverslips (#1, L18 mm, Marienfeld, Lauda-
K€onigshofen, Germany) and cultured in a 12-well plate (Nunc,
Langenselbold, Germany) at 37 C and 5% CO2. For experimental
procedure cells of a conﬂuency of 80e90% were used. For the cAMP
assay, 1  103 cells per well were seeded in a 96-well plate (Nunc)
and cultivated at 37 C and 5% CO2 until reaching a conﬂuency of
90%.
HEK293 cells overexpressing b2-adrenergic receptor-GFP fusion
proteins produced by our group [6] were cultivated and plated onto
heat-sterilized glass coverslips as described above for HASM cells.
After reaching 70e80% conﬂuency, cells were used for live cell
imaging.
2.3. Live cell imaging
Pictures of live HEK293 cells stably expressing b2AR-GFP were
taken with an Axiovert® 200M (Zeiss, Jena) ﬂuorescence micro-
scope equipped with argon laser, beam splitter HFT 488/543, oil
immersion objective (Plan Apochromat 63/1.4), bandpass ﬁlter BP505-530, and pinhole 96 mm was used. Pictures were recorded
with a AxioCam® (Zeiss, Jena, resolution of 512  512 pixels)
camera. The camera was controlled by the Axiovision® (Zeiss, Jena,
release 4.7) software. Pictures shown are representatives of three
independently performed experiments. Prior to measurements
cells pretreated for 24 h with 1 mM of test compound or 0.1%
methanol as vehicle (control cells) were washed three times with
Locke's solution (154.0 mM NaCl, 5.6 mM KCl, 2.3 mM CaCl2 dihy-
drate, 1.0 mMMgCl2 hexahydrate, 3.6 mM NaHCO3, 5.0 mM HEPES,
and 2.0 mM D-(þ)-glucose monohydrate, pH 7.3). Coverslips were
mounted on a coverslip carrier above the microscope objective.
Incubation volume was 300 mL. For internalization experiments,
cells were incubated for 30 min with 1 mM terbutaline hemisulfate.
All measurements were performed at 20 C.2.4. Fluorescence correlation spectroscopy (FCS)
Measurements were performed with a ConfoCor 1 instrument
(Zeiss, Jena, Germany) equippedwith an argon laser (LGK 7812ML 2,
Lasos, Jena, Germany). For excitation, the 514 nm line of the laser was
used and focused through a water immersion objective (C-Apo-
chromat, 63  /1.2) into the sample (excitation ﬁlter 515 FS 10-25,
Andover, Salem, MA, laser power p514 ¼ 2.4 kW/cm2). The emitted
ﬂuorescence was separated from the excitation light with a dichroic
ﬁlter (FT540, Andover) and from the background noise with a
bandpass ﬁlter (EF530-600, Andover). After passing a variable
pinhole (40 mm), the intensity ﬂuctuations were detected by an
avalanche single-photon counting module (SPCM-AG Series, Perki-
nElmer Optoelectronics, Fremont, ON) and correlated over time us-
ing a digital hardware correlator (ALV-5000, ALV, Langen, Germany)
to generate autocorrelation curves. For FCS measurements, the laser
focus was positioned on the upper plasma membrane of the cell by
motoraided scanning of the cell in the z-direction. Using theMATLAB
Software (version R2009a, The MathWorks Inc., Natick, MA) auto-
correlation curves were evaluated with the autocorrelation function.
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where Nj is the average number of molecules of species j in the
volume element, tDj is the diffusion time constant of species j, t is
the correlation time, u0 is the radius of the observation volume in
the focal plane, z0 is the radius of the observation volume in the z-
direction, Dj is the translational diffusion coefﬁcient of species j, t is
the triplet state, ttrip is the triplet time, Qj is the quantum yield
factor, sj is the absorption coefﬁcient, hj is the ﬂuorescence quan-
tumyield, and gj is the ﬂuorescence detection efﬁciency of species j.
HASM cells pretreated for 24 h with 0.01 mM, 0.1 mM, and 1.0 mM
b-hederin, respectively, and subsequently washed three times with
Locke's solution were used for receptor binding studies. FCS
Fig. 1. Live cell images of HEK293 cells overexpressing b2AR-GFP. Unstimulated control cells without pretreatment (A) and pretreated for 24 h with 1 mM a-hederin (C) and b-
hederin (E). Following stimulation with 1 mM terbutaline for 30 min (B, D, F).
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Alexa532-NA (n ¼ 8).
Association kinetic of Alexa532-NA in concentrations of 5 nM
and 20 nM at b2-adrenergic receptors were measured time-
dependently for 25 min. Using the Prism® (version 5.04, Graph-
Pad Software Inc., La Jolla, CA) software and the evaluation tool
“nonlinear regression, association kinetics e two and more con-
centration”maximum number of binding sites (Bmax) of HASM cells
pretreated with 1 mM b-hederin and control cells were determined.2.5. cAMP assay
The cAMP assay was performed using the HitHunter cAMP assay
kit for adherent cells (Amersham Bioscience, Freiburg, Germany)
following the manufacturer's instructions. HASM cells wereincubated for 24 h with 1 mM b-hederin. 0.1% methanol was added
as a vehicle to control cells. Before the cAMP concentration was
examined, cells were further pretreated with 10 mM terbutaline,
10 mM forskolin or simultaneously with 10 mM terbutaline and
10 mM forskolin for 10 min at 37 C (n ¼ 4). The ﬂuorescence was
measured using a GENios microplate reader (Tecan, Crailsheim,
Germany) applying an excitation wavelength of 530 nm and an
emission wavelength of 610 nm. Data processing was conducted
with Magellan 3.0 software (Tecan).2.6. Statistical data evaluation
Statistical data evaluation was performed with one factorial
analysis of variance (ANOVA), after their normal distribution was
ensured by means of a D'Agostino & Pearson normality test. A
Fig. 2. Autocorrelation curves for the Alexa532-NA binding to untreated (◊, black) and
a-hederin pretreated (B, red) HASM cells. Right-shift of the autocorrelation curve
indicates an increased Alexa532-NA binding to ß2AR of b-hederin (1 mM, 24 h) pre-
treated cells. (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.)
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were considered to be signiﬁcant for p values of <0.05.
3. Results
3.1. HPLC-MS analysis of an ivy leaves dry extract
By means of high-performance liquid chromatography-mass
spectrometry (HPLC-MS) analysis 17 ingredients were identiﬁed
from an ivy leaves dry extract (EA 575, DER 5-7.5:1, 30%m/m EtOH),
leading to the detection of protocatechuic acid (1), neochlorogenic
acid (2), chlorogenic acid (3), rutin (4), kaempferol-3-O-rutinoside
(5), 3,4-, 3,5- and 4,5-dicaffeoylquinic acid (6,7,8) as well as
hederacoside B, C, D and F (9,10,11,12), hederaginin-3-O-glucoside
(13), a-, b- and d-hederin (14,15,16). In addition, cryptochlorogenic
acid (17) was identiﬁed in ivy leaves dry extracts for the ﬁrst time.
Assignment of the ingredients in the HPLC chromatogram was
performed through comparison of UV and MS data and retention
times of corresponding reference substances (Table 1,
Supplemental material). The molecular structures of the com-
pounds tested are given in Figs. 1e2 of the Supplemental material.
3.2. Internalization of b2-adrenergic receptors
The main ingredients 1e9, 14, 15, 17 were investigated on their
inﬂuence on the internalization of b2-adrenergic receptor-GFP
fusion proteins (b2AR-GFP) in stably transfected HEK293 cells us-
ing ﬂuorescence microscopy. Stimulation with 1 mM terbutaline
(b2-agonist, positive control) for 30 min led to a pronounced
endocytotic b2-adrenergic receptor (ß2AR) internalization, which
was recognized by large intracellular vesicles positive for the
receptor-ligand complexes (Fig. 1B). Preincubation with 1 mM a-
hederin (negative control) for 24 h clearly led to an inhibition of
ß2AR internalization under stimulating conditions. A similar result
was found for a 24 h pretreatment with 1 mM b-hederin. Compared
to the positive control, similar vesicles were not observed in a-
hederin and b-hederin pretreated cells, respectively (Fig. 1B, D, F).
Live cell recordings of a-hederin and b-hederin pretreated cells,
respectively, clearly demonstrate the inhibition of ß2AR internali-
zation for the duration of 30 min after addition of 1 mM terbutaline,
compared to control cells (video 1e3, supplemental material).
Supplementary video related to this article can be found at
http://dx.doi.org/10.1016/j.pupt.2014.09.002.
In contrast, all other tested compounds (1e9, 17) showed no
effect under identical experimental conditions (1 mM test com-
pound for 24 h, then 1 mM terbutaline for 30 min). The corre-
sponding ﬂuorescence microscope images clearly demonstrated
internalization of ß2AR after stimulation that did not differ quali-
tatively from control cells (Fig. 3, Supplemental material). For this
reason, these compounds (1e9,17) were not considered any further
for the following investigations.
3.3. b2-adrenergic receptor binding studies
Receptor binding studies were performed using ﬂuorescence
correlation spectroscopy (FCS) to investigate the inﬂuence of b-
hederin on the binding behavior of ß2AR in human airway smooth
muscle (HASM) cells. 5 nM of Alexa532-NA (arterenol, labeled with
Alexa-532) was used as ﬂuorescent ß2AR ligand. After an incuba-
tion time of 15 min, the laser focus was positioned on the upper
membrane surface and ﬂuctuations in ﬂuorescence intensity were
measured for 60 s. Evaluation of the autocorrelation curve revealed
a diffusion time constant tfree of 0.056 ± 0.001 ms (n ¼ 8) for freely
diffusing Alexa532-NA and two diffusion time constants for
receptor-ligand complexes with unrestricted and hindered lateralmobility of tbound1 of 1.1 ± 0.4 ms (n ¼ 8) and tbound2 of
64.2 ± 47.6 ms (n ¼ 8), respectively (Fig. 2). In these experiments
diffusion time constants were distributed with 67.0 ± 8.9% for tfree,
24.0 ± 7.1% for tbound1, and 9.0 ± 2.3% for tbound2. The total binding
was 33.0 ± 8.9% (Fig. 3). Diffusion coefﬁcients of D1 ¼9.1 ± 0.2 mm2/
s and D2 ¼ 0.15 ± 0.02 mm2/s were calculated for the different
receptor-ligand complexes from tbound1 and tbound2 values.
After pretreatment of HASM cells with 1 mM b-hederin for 24 h
the ß2AR binding displayed a statistically signiﬁcant increase to
44.1 ± 11.5% which was distributed with 36.0 ± 9.5% for tbound1 and
8.1 ± 2.6% for tbound2, respectively (n¼ 8, p < 0.05) (Fig. 3). Thus, the
increased binding was selectively found for the receptoreligand
complex with unrestricted lateral mobility. In order to clarify
whether the increase in ligand binding is due to an inhibition of
receptor internalization or possibly to an increased receptor
expression, the receptor density was determined by measuring the
association kinetic of Alexa532-NA at concentrations of 5 nM and
20 nM over 25 min. Data evaluation revealed maximum number of
binding sites (Bmax) values of 27.6 ± 1.8 nM (n ¼ 10) and
31.6 ± 2.3 nM (n ¼ 3) for b-hederin pretreated cells and control
cells, respectively, which were not statistically different. While the
diffusion time constant with tbound1 of 0.9 ± 0.1 mswas not affected
by the b-hederin pretreatment, hindered diffusion with tbound2 of
206.8 ± 218.7 ms was further restricted, compared to control cells.
Whereas a pretreatment with 0.01 mM of b-hederin did not show
any effect, the receptor binding was slightly increased with 0.1 mM
of b-hederin, which was not statistically signiﬁcant (Fig. 3).
3.4. cAMP levels in human airway smooth muscle cells
The increased ß2AR binding was further conﬁrmed by deter-
mination of intracellular cAMP levels of human airway smooth
muscle (HASM) cells under stimulating conditions (10 mM forskolin
and 10 mM terbutaline) after pretreatment with 1 mM b-hederin for
24 h. Compared to control cells, a statistically signiﬁcant increase of
17.5 ± 6.4% (n¼ 4, p < 0.05) in the cAMP formationwas found for b-
hederin pretreated HASM cell after stimulation with 10 mM terbu-
taline for 10 min. cAMP formation was further enhanced by
simultaneous stimulation with 10 mM terbutaline and 10 mM for-
skolin to a value of 24.2 ± 5.8% (n ¼ 4, p < 0.001). The sole stimu-
lation with 10 mM forskolin of a-hederin pretreated cells also
tended to a higher cAMP level, which was not statistically signiﬁ-
cant compared to the corresponding control (Fig. 4).
Fig. 3. Alexa532-NA binding to ß2AR on HASM cells. Occurrence of free and bound
Alexa532-NA and lateral mobility of b2AR-ligand complexes with tbound1 and tbound2 of
control cells (white) and cells pretreated with 0.01 mM (light gray), 0.1 mM (dark gray)
and 1 mM (black) b-hederin for 24 h (b) (n ¼ 8, p < 0.05).
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The b2-adrenergic receptor (ß2AR) is mainly responsible for the
relaxation of smooth muscle by adrenaline stimulation. Thus,
activation of ß2AR e.g. leads to a relaxation of the bronchial tubes.
Alveolar type II cells of the alveoli synthesize and secrete surfactant,
a surface-active lipoprotein complex, that increases pulmonary
compliance and prevents collapse of the lung at the end of expi-
ration. The surfactant production is mediated among others by the
activation of ß2AR [10].
Ivy leaves dried extracts are used for the treatment of acute and
chronic obstructive airway diseases. The secretolytic and bron-
chospasmolytic effects have been explained by an indirect b2-
mimetic mode of action, mediated by a-hederin through an inhi-
bition of internalization of ß2AR [6,7]. The thus elevated
b2-adrenergic responsiveness was conﬁrmed by an increased ß2ARFig. 4. Accumulation of cAMP in HASM cells comparing control cell levels (basal) with
cells stimulated with 10 mM terbutaline, 10 mM forskolin or simultaneously with 10 mM
terbutaline and 10 mM forskolin for 10 min before (white) and after pretreatment with
1 mM b-hederin for 24 h (gray) (n ¼ 4, p* < 0.05, p*** < 0.001, n.s. ¼ not signiﬁcant).binding and elevated cAMP levels of a-hederin pretreated alveolar
type II (A549) cells and human airway smoothmuscle (HASM) cells,
respectively [6]. This increased cAMP signaling induces alveolar
type II cells to enhance the formation and secretion of surfactant,
which reduces the viscosity of viscous mucus and therefore results
in the secretolytic effect of ivy preparations proven in clinical
studies [1-4]. Bronchial muscle cells respond to the increased cAMP
level with the PKA-induced phosphorylation of the myosin light-
chain kinase (MLCK) and therefore to a diminished activation po-
tential of the MLCK by the calmodulin/Ca2þ complex [11].
Furthermore, the release of Ca2þ from intracellular stores and the
inﬂux through calcium channels is blocked [12]. Via the inhibition
of the MLCK and the reduced intracellular calcium concentration of
bronchial muscle cells it is possible to explain the broncho-
spasmolytic activity of ivy preparations seen within patients [4].
Wolf et al. could demonstrate an explicit a-hederin dose-
dependent improvement of the isoprenaline-induced muscle
relaxation on pre-contracted bovine tracheal muscle stripes by
isometric tension measurements [7]. Additionally, in vitro anti-
spasmodic activity of saponins, ﬂavonoids and dicaffeoylquinic
acids was investigated using isolated guinea-pig ileum with
acetylcholine as spasmogen. Obviously, saponins contribute most
to the antispasmodic activity [13].
The ivy leaves dried extract (EA 575, DER 5-7.5:1, 30% m/m
EtOH) mainly consists of saponins, ﬂavonoids and phenolic acids.
The main constituents of each natural product class were investi-
gated on their inﬂuence on the internalization of ß2AR under
stimulating conditions. Stably transfected HEK293 cells over-
expressing the ß2AR as a GFP fusion protein were used for these
experiments. b-Hederin and hederacoside B were tested as repre-
sentatives of the saponins.
b-Hederin inhibited internalization of ß2AR under stimulating
conditions (Fig. 1F). This effect has already been described for the
structurally related a-hederin which served in the present study as
a negative control (Fig. 1D). In contrast, hederacoside B showed no
effect and thus behaved similarly to hederacoside C (Fig. 1,
Supplemental material) [6,8].
The ﬂavonoids rutin and kaempferol-3-O-rutinoside did not
inﬂuence the internalization of ß2AR (Fig. 1, Supplemental
material). On the other hand, ﬂavonoids may have the ability to
affect the regulation of b-adrenergic receptors. It has recently been
described that hyperoside mediates an internalization of b1-
adrenergic receptors (ß1AR) under non-stimulating conditions,
whereas the ß2AR remains in the plasma membrane [14,15].
Finally, the phenolic acids protocatechuic acid, neochlorogenic
acid, chlorogenic acid, 3,4-, 3,5- and 4,5-dicaffeoylquinic acid, and
cryptochlorogenic acid were investigated. Remarkably, crypto-
chlorogenic acid was identiﬁed as an ingredient of an ivy leaves dry
extract (EA 575, DER 5-7.5:1, 30% m/m EtOH) for the ﬁrst time. Cells
pre-treated with these substances showed a clear internalization of
ß2AR after subsequent stimulation with terbutaline (Fig. 1,
Supplemental material). Obviously, the tested phenolic acids were
not able to inhibit this regulatory process.
For further investigations b-hederin was only used because all
other test substances had no effect on the internalization of ß2AR.
Receptor binding studies were conducted using ﬂuorescence cor-
relation spectroscopy (FCS) to conﬁrm the increased b2-adrenergic
responsiveness, expected for b-hederin pretreated HASM cells.
Evaluation of the autocorrelation curve indicated a statistically
signiﬁcant increase in the total Alexa532-NA binding from
33.0 ± 8.9% to 44.1 ± 11.5% which was selectively found for
receptor-ligand complexes with unrestricted lateral mobility
(tbound1) (Fig. 3). This effect was dose-dependent for b-hederin.
Evaluation of the association kinetics of Alexa532-NA revealed
comparable b2AR densities with Bmax values of 27.6 ± 1.8 nM and
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respectively. Since b-hederin does not affect the b2AR expression in
HASM cells, inhibition of receptor internalization appears to be
responsible for the increased ligand binding. Comparable results
were found for a-hederin with alveolar type II (A549) cells [6].
Sieben et al. have been able to demonstrate that under stimulating
conditions the number of ß2AR increases with hindered lateral
mobility [16]. This ﬁnding indicates a possible internalization, since
it can be assumed that ß2AR are nearly immobilewithin coated pits.
A redistribution of b2AR-Alexa532 complexes to slower diffusion
time constants was observed in A549 cells after terbutaline stim-
ulation, which correlated temporally with the internalization
prozess [9]. The increase of receptor-ligand complexes with unre-
stricted lateral mobility in b-hederin pretreated HASM cells in-
dicates a decreased ß2AR internalization. This should lead to an
increased b2-adrenergic responsiveness and consequently to
increased cAMP formation. In fact, in b-hederin pretreated HASM
cells the cAMP level was statistically signiﬁcant enhanced by
17.5 ± 6.4% and 24.2 ± 5.8% under terbutaline and terbutaline/for-
skolin stimulating conditions, respectively, compared to control
cells (Fig. 4). Comparable results were recently found for a-hederin
pretreated HASM cells [6].
Although the b2-mimetic effect of the ivy leaves dry extrakt (EA
575, DER 5-7.5:1, 30% m/m EtOH) according to the data available so
far is presumably mediated mainly by the existing saponins, the
ﬂavonoids and phenolic acid may also contribute to the clinical
efﬁcacy. As an example, rutin inhibits the NO-synthesis in lipo-
polysaccharide (LPS) stimulated RAW 264.7 cells via the NF-КB-
dependent iNOS gene transcription [17]. Additionally, an anti-
inﬂammatory effect could be shown within an animal model.
Here, rutin inhibited the carrageenan-induced (i) edema formation
of rat paws and (ii) arthritis in rats within the acute as well as in the
chronic phase, respectively [18,19]. Antioxidative effects of rutin
have been found within a variety of analysis including the lipid
peroxidation assay [20].
An anti-inﬂammatory and antioxidative effect has also been
described for caffeoylquinic acid derivatives. With the ovalbumin-
induced allergic asthma mouse model, the inhibitory effect of
chlorogenic acid on the synthesis of IgE and TH2-cell speciﬁc cy-
tokines (e.g. IL-4, IL-5) could be shown [21]. Upon oral application,
chlorogenic acid diminished the carrageenan-induced edema for-
mation of rat paws, in a dose-dependent manner. The authors
exclude an inhibition of the prostaglandin E2 (PGE2) synthesis as
mode of action and actually suggest the inhibition of the TNF-a or
IL-6 synthesis [22]. Within the mouse model it could be shown that
chlorogenic acid application protect from LPS-induced acute lung
injury [23]. Chlorogenic acid inhibits the LPS-induced upregulation
of the cyclooxygenase 2 (COX2) expression in RAW 264.7 cells,
mediated through the inhibited NF-КB-dependent gene activation,
which as a result reduces the PGE2 synthesis and explains the anti-
inﬂammatory effect [24]. In bovine liver microsomes chlorogenic
acid reduces the iron-induced lipid peroxidation in a dose depen-
dent manner. The production of hydroxyl radicals is hereby clearly
prevented by the formation of chlorogenic acideiron complexes
[25]. An antioxidative effect of chlorogenic acid was also found in
the intestinal ischemia-reperfusion model in rats [26]. The anti-
oxidative activity of neochlorogenic acid, cryptochlorogenic acid
and chlorogenic acid could be determined by means of electron
spin resonance (ESR) spectroscopywithin a xanthine oxidase (XOD)
assay. All three compounds were able to scavenge superoxide anion
radicals. In addition, a preventive effect toward the oxidation of
linoleic acid methyl ester could also be identiﬁed [27]. 3,4-
dicaffeoylquinic acid inhibits the phorbol 12-myristate 13-acetate
(PMA) induced COX-2 expression and subsequently the formation
of PEG2 in RAW 264.7 cells. As a consequence, the catalytic activityof JNK/p38MAP kinases is blocked and the activation of C/EBPb and
AP-1 is inhibited [28]. 3,5- and 3,4-dicaffeoylquinic acid showed
within the DPPH assay, which utilizes the redox reaction of stable
2,2-diphenyl-1-picrylhydrazyl radicals, antioxidative properties,
that are more pronounced in comparison to ascorbic acid. This
antioxidative properties are assumed to result from the ortho-
dihydroxy-phenolic moiety as well as from the eCH]CHeCOOR
group. 3,5- and 4,5-dicaffeoylquinic acid inhibit the LPS-induced
NO-Synthesis in RAW 264.7 cells and also the LPS-induced
expression of the NO-synthase (iNOS) and the cyclooxygenase-2
(COX-2) as well as their respective mRNA synthesis in human
keratinocytes (HaCaT) [29]. Anti-inﬂammatory effects of an ivy
leaves dried extract (EA 575, DER 5-7.5:1, 30% m/m EtOH), as
testiﬁed by a reduced leucocyte count and mucoprotein content
within the blood sera of children suffering from chronic bronchitis,
following inhalative treatment, can be probably assigned to the
presence of ﬂavonoids and phenolic acids [30]. Preclinical studies
suggest that also a-hederin may have an antioxidative effect, found
in different assays like DPPH, free radical scavenging, hydrogen
peroxide scavenging. As an example, a-hederin showed an inhibi-
tion on lipid peroxidation of linoleic acid emulsion [31].5. Conclusions
Herbal drugs represent an indispensable option for the treat-
ment of a variety of diseases. The ivy leaves dry extract (EA 575) is
used for the treatment of acute and chronic obstructive airway
diseases. The main ingredients belong to the group of saponins,
ﬂavonoids and phenolic acids and their inﬂuence on the b2-
adrenergic receptor of human airway smooth muscle cells was
investigated by ﬂuorescence correlation spectroscopy measure-
ments, internalization studies and cAMP assays. Within this pre-
sent work it was possible to identify two saponins b-hederin and
hederacoside B as further components of an ivy leaves dry extract
presumably responsible for the b2-mimetic effects.Acknowledgments
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